文献速递病毒性肝炎

迈向乙型肝炎病毒感染治愈:病毒抑制联合免疫调节的组合治疗及长期结局

Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
PubMed 文献 · J Infect Dis · 2017-01-01

慢性乙型肝炎病毒(HBV)感染仍是全球重大健康负担,现有治疗包括核苷(酸)类似物(NAs)和干扰素或聚乙二醇干扰素。NA治疗安全但停药后病毒学复发率高,需长期甚至终身用药;聚乙二醇干扰素疗程有限、应答更持久且无病毒耐药,但单药持续应答率低且副作用常见。由于HBV共价闭合环状DNA和整合基因组在感染肝细胞核内稳定存在,完全清除HBV罕见,持续HBsAg丢失(伴或不伴抗-HBs血清学转换,即功能性治愈)被推荐为理想治疗终点。理论上,联合不同作用机制的抗病毒药物(病毒抑制联合免疫调节,如NA联合聚乙二醇干扰素)是治疗慢性乙型肝炎的有前景策略。近期研究证实同时给药(de novo联合)或序贯联合(在持续NA治疗基础上加用聚乙二醇干扰素)在病毒学和血清学方面优于单药治疗,但组合治疗长期结局的数据有限。本综述总结了当前旨在治愈慢性HBV感染的组合治疗。

要点

  • NA治疗安全但停药后病毒学复发率高,需长期甚至终身用药。
  • 聚乙二醇干扰素疗程有限、应答更持久且无病毒耐药,但单药持续应答率低且副作用常见。
  • 持续HBsAg丢失(伴或不伴抗-HBs血清学转换,即功能性治愈)是理想治疗终点。

核心结论

  • NA联合聚乙二醇干扰素(de novo或序贯联合)在病毒学和血清学方面优于单药治疗,但组合治疗长期结局的数据有限。

研究设计与样本

  • 综述,总结当前旨在治愈慢性HBV感染的组合治疗。

主要发现

  • NA治疗安全且耐受性良好,但停药后病毒学复发率高,需终身用药。
  • 聚乙二醇干扰素疗程有限、应答更持久且无病毒耐药,但单药持续应答率低且副作用常见。
  • HBV共价闭合环状DNA和整合基因组在感染肝细胞核内稳定存在,完全清除HBV罕见。
  • 近期研究证实同时给药(de novo联合)或序贯联合(在持续NA治疗基础上加用聚乙二醇干扰素)在病毒学和血清学方面优于单药治疗。

关键数值与推荐

  • 持续HBsAg丢失,伴或不伴抗-HBs血清学转换(即功能性治愈),被推荐为抗HBV治疗的理想终点。

临床怎么用

  • 可考虑NA联合聚乙二醇干扰素(de novo或序贯联合)以追求功能性治愈,但需权衡长期结局数据有限的现状。

局限性

  • 组合治疗长期结局的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, the approved therapeutic regimens include nucleos(t)ide analogues (NAs) and either interferon or pegylated interferon. NA therapy is generally safe and well tolerated, but the rate of posttreatment virologic relapse is high, making NA treatment a lifetime commitment. The benefits of pegylated interferon treatment include a finite duration, more-durable response and absence of viral resistance. However, sustained response to interferon alone is achieved only in a minority of patients, and side effects are common, which limit its clinical use. Given that HBV covalently closed circular DNA and the integrated HBV genome persist stably in the nuclei of infected hepatocytes, elimination (complete cure) of HBV is rarely achieved. After completion of treatment, sustained HBV surface antigen loss, with or without seroconversion to HBV surface antibody positivity (ie, functional cure), is therefore recommended as the ideal end point for anti-HBV treatment, despite the lack of complete eradication of HBV. Theoretically, combination of antiviral agents with differential mechanisms of actions on HBV, including viral suppression combined with immune modulation (as occurs during treatment with NA plus pegylated interferon), is an encouraging strategy to treat chronic hepatitis B. Recent studies have confirmed certain virological and serological advantages of simultaneous administration of NA and pegylated interferon (de novo combination therapy) or addition of pegylated interferon to ongoing NA therapy (sequential combination therapy) over monotherapy. Few data exist, however, on the long-term outcomes of patients receiving combination therapy. This review summarizes current combination therapy developed to cure chronic HBV infection.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wu D, Ning Q. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome. J Infect Dis. 2017. PMID: 29156046. doi:10.1093/infdis/jix355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。